Status:
NOT_YET_RECRUITING
Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients
Lead Sponsor:
Chengdu New Radiomedicine Technology Co. LTD.
Conditions:
Solid Tumor Malignancy
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
Stage 1 (Safety study for 68Ga-NRT6020 Injection): The goal of this clinical trial stage is to evaluate the safety of 68Ga-NRT6020 Injection in participants with advanced solid tumors. The study will...
Detailed Description
During the study, 68Ga-NRT6020 served as the companion diagnostic agent for 177Lu-NRT6020 to select eligible patients. This stage 2 and stage 3 of the study is designed as a multi-center, multiple-dos...
Eligibility Criteria
Inclusion
- Key
- Male or female participants aged 18-80;
- Histologically or cytologically confirmed advanced solid tumors; advanced solid tumors patients who have failed prior standard therapies or deemed unsuitable for standard therapies (only for stage 2 and stage 3);
- Have at least one measurable lesion as per RECIST v1.1/PERCIST criteria;
- For stage 2 and stage 3, a positive 68Ga-NRT6020 Injection PET/CT imaging results is required;
- Participants must have adequate organ function;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥3 months;
- For women of childbearing potential, a negative blood pregnancy test within 3 days before the first dose is required, and fertile male and female participants of childbearing potential must agree to use effective contraception with their partners from the signing of the informed consent form until 12 months after the last dose of the investigational drug.
- Key
Exclusion
- Known allergy to 68Ga-NRT6020 Injection, 177Lu-NRT6020 Injection, or any of their ingredients, such as alcohol;
- Presence or suspicion of primary central nervous system tumors or intracranial metastasis;
- For stage 1: Received prior antitumor treatments within 7 days before the investigational drug dosing, and/or plan to receive antitumor treatments during the safety observation period; For stage 2 and stage 3: Received prior antitumor treatments within 4 weeks before the initial investigational drug dosing, including chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc.;
- History of other malignancies within 5 years prior to the first dose of the investigational drug, excluding cured non-melanoma skin cancer, early-stage papillary thyroid cancer, and cervical carcinoma in situ;
- Presence of severe or uncontrolled cardiac diseases requiring treatment;
- High risk of bleeding;
- Active syphilis or human immunodeficiency virus (HIV) antibody positive;
- HBsAg-positive or HBcAb-positive with HBV-DNA levels above the detection limit;
- Failure to alleviate previous antitumor treatment toxicities to Grade 0 or 1 according to CTCAE v5.0;
- Participate in any other clinical trials within 1 month before the first dosing of 68Ga-NRT6020 Injection.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT06911489
Start Date
July 1 2025
End Date
December 1 2027
Last Update
April 4 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.